Related Experiment Video

Updated: Jun 4, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

[mTOR inhibitor]

Kei Muro1

  • 1Dept. of Clinical Oncology, Aichi Cancer Center Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2011
PubMed

Insights

Mammalian target of rapamycin (mTOR) signaling drives cancer growth and proliferation. Inhibiting mTOR shows promise as an antitumor strategy, particularly in renal cell cancer and pancreatic neuroendocrine tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) is a key signaling pathway downstream of PI3K/AKT, frequently activated in various cancers.
  • mTOR regulates mRNA translation for proteins involved in cell cycle, apoptosis, and survival, promoting cancer cell proliferation and angiogenesis.
  • mTOR also influences the growth and proliferation of cancer vascular endothelial cells.

Purpose of the Study:

  • To review the role of mTOR in cancer development and progression.
  • To discuss the therapeutic potential of mTOR inhibitors in cancer treatment.
  • To highlight the need for biomarkers predicting mTOR inhibitor efficacy and toxicity.

Main Methods:

  • Literature review of studies on mTOR signaling in cancer.
  • Analysis of clinical trial data for mTOR inhibitors.
  • Examination of preclinical research on mTOR targeted therapies.

Main Results:

  • mTOR inhibition demonstrates antitumor effects by suppressing cancer cell proliferation and angiogenesis.
  • mTOR inhibitors are established as standard treatments for renal cell cancer and show utility in pancreatic neuroendocrine tumors.
  • The development of effective biomarkers for predicting mTOR inhibitor response and toxicity is an ongoing challenge.

Conclusions:

  • mTOR is a critical mediator of cancer cell growth and angiogenesis, making it a viable therapeutic target.
  • mTOR inhibitors represent a significant advancement in cancer therapy, with established roles in specific malignancies.
  • Future research should focus on identifying predictive biomarkers to optimize mTOR inhibitor therapy and improve patient outcomes.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...